The Effects of Bromelain Supplement in Patients With Ulcerative Colitis

National Nutrition and Food Technology Institute

Status: Enrolling

Conditions: Primary Sclerosing Cholangitis; Ulcerative Colitis

Treatments: Dietary Supplement: Bromlein; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT06351696

43008563

Details and patient eligibility

About

In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks.

IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.

Enrollment: 84 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• active mild to moderate UC
• no other chronic disorders

Exclusion criteria

• changed the type and dosage of their medication in the last month
• those who have relapses that required hospitalization and change the type and dosage of medications during the intervention
• patients who do not want to continue the study protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

84 participants in 2 patient groups, including a placebo group

Intervention

Active Comparator group

Description:

Bromleine

Treatment:

Dietary Supplement: Bromlein

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Other: Placebo